Clinical Trials
3 trialsNCT05989828 2026-05-19
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
University of Southern California
Phase 1 Recruiting
NCT06435351 2026-04-01
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT05539365 2025-01-29
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 2 Withdrawn